Recursion Pharmaceuticals is trading at $4.13, up 10.43% in live trading, amid October 15 clinical updates. - REC-4881 updates included a 47% median reduction in total polyp burden, alongside early REC-1245 responses. - Sanofi optioned a development candidate, triggering a $10 million milestone payment. - The company priced a $200 million stock offering, a potential countervailing factor; available price context lacks volume, so trading activity cannot be assessed.